Simple, 3-Step, Patient-Friendly Delivery
Somatuline® Depot (lanreotide) Injection is the only longacting SSA therapy that is ready-to-use in a prefilled syringe1,11
- Prefilled syringe allows delivery of a complete dose every time
- No short-acting injection necessary
- Patient- and professional-friendly injection designed with patients in mind1
- Administered via the deep subcutaneous route
- Small syringe volume of only 0.3 - 0.5 mLc
- Therapeutic levels can be attained at 24 hours after the first injection
-
The only 28-day somatostatin analog that does not require reconstitution1,11
Convenient injection: The only long-acting somatostatin analog for acromegaly with a deep subcutaneous injection in a prefilled syringe that needs no reconstitution1,11
Simple, 3-step injection procedure.
Step 1:
Insert Needle
Step 2:
Inject Medication
Step 3:
Remove Needle
*Please note that this coverage is not available for patients on
Medicare, Medicaid, and residents of Massachusetts.
Indication and Important Safety Information
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.
There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.
A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).
For Full Prescribing Information, click here.
